AB Science Reports Key Developments and Financial Results

Ab Science ( (ABSCF) ) has released its Q2 earnings. Here is a breakdown of the information Ab Science presented to its investors.

AB Science S.A. is a French biopharmaceutical company focused on the research, development, and commercialization of synthetic therapeutic molecules for diseases with high medical needs, particularly in the central nervous system, cancer, and inflammatory diseases.

In its latest earnings report for the first half of 2025, AB Science highlighted several clinical development milestones, including advancements in its masitinib platform and the designation of its molecule AB8939 as an orphan drug for acute myeloid leukemia by the European Medicines Agency. Financially, the company reported a net loss, but it successfully raised capital through private placements to support ongoing clinical programs.

Key financial metrics showed a decrease in net sales to €515,000 from €560,000 in the previous year, primarily due to a temporary drop in veterinary medicine sales. Operational losses decreased by 23.8% to €2.728 million, attributed to reduced research and development expenses and administrative costs. However, the net loss increased by 15.8% to €5.177 million, impacted by financial charges.

Strategically, AB Science secured regulatory approvals for critical clinical trials and strengthened its intellectual property portfolio with new patents in Canada and the U.S. The company also negotiated a two-year delay in state-guaranteed loan repayments, providing financial flexibility.

Looking ahead, AB Science remains focused on advancing its clinical programs, particularly for masitinib and AB8939, while exploring partnership opportunities to bring its therapies to market. The management anticipates continued investment in drug discovery to expand its pipeline, contingent on securing necessary financial resources.